(Q36969778)

English

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

scientific article published on 31 July 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 August 2017

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation (English)

1 reference

Europe PubMed Central

17 August 2017

0 references

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

Natalia de las Heras

object named as

Natalia de Las Heras

11

0 references

Javier de la Rubia

object named as

Javier de la Rubia

20

0 references

Norma C. Gutiérrez

object named as

Norma C Gutiérrez

9

0 references

24

object named as

Alberto Orfao

1 reference

Europe PubMed Central

17 August 2017

author name string

Bruno Paiva

1

1 reference

Europe PubMed Central

17 August 2017

Maria-Belén Vidriales

2

1 reference

Europe PubMed Central

17 August 2017

Jorge Cerveró

3

1 reference

Europe PubMed Central

17 August 2017

Gema Mateo

4

1 reference

Europe PubMed Central

17 August 2017

Jose J Pérez

5

1 reference

Europe PubMed Central

17 August 2017

Maria A Montalbán

6

1 reference

Europe PubMed Central

17 August 2017

Anna Sureda

7

1 reference

Europe PubMed Central

17 August 2017

Laura Montejano

8

1 reference

Europe PubMed Central

17 August 2017

Alfonso García de Coca

10

1 reference

Europe PubMed Central

17 August 2017

Maria V Mateos

12

1 reference

Europe PubMed Central

17 August 2017

Maria C López-Berges

13

1 reference

Europe PubMed Central

17 August 2017

Raimundo García-Boyero

14

1 reference

Europe PubMed Central

17 August 2017

Josefina Galende

15

1 reference

Europe PubMed Central

17 August 2017

Jose Hernández

16

1 reference

Europe PubMed Central

17 August 2017

Luis Palomera

17

1 reference

Europe PubMed Central

17 August 2017

Dolores Carrera

18

1 reference

Europe PubMed Central

17 August 2017

Rafael Martínez

19

1 reference

Europe PubMed Central

17 August 2017

Alejandro Martín

21

1 reference

Europe PubMed Central

17 August 2017

Joan Bladé

22

1 reference

Europe PubMed Central

17 August 2017

Juan J Lahuerta

23

1 reference

Europe PubMed Central

17 August 2017

Jesús F San Miguel

25

1 reference

Europe PubMed Central

17 August 2017

GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups

26

1 reference

Europe PubMed Central

17 August 2017

language of work or name

0 references

publication date

31 July 2008

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

112

1 reference

Europe PubMed Central

17 August 2017

4017-4023

1 reference

Europe PubMed Central

17 August 2017

10

1 reference

Europe PubMed Central

17 August 2017

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

Conventional diagnostics in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

Minimal residual disease monitoring in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

Phenotypic difference of normal plasma cells from mature myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

High-dose melphalan with autologous bone marrow transplantation for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

29 September 2017

The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

27 June 2018

Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

4 September 2018

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

4 September 2018

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

4 September 2018

Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

4 September 2018

Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

4 September 2018

Immunophenotyping of plasma cells in multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

4 September 2018

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

4 September 2018

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

4 September 2018

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

4 September 2018

Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

20 October 2018

Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

20 October 2018

Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

20 October 2018

Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2581991

20 October 2018

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669875

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669875

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669875

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669875

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669875

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669875

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669875

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18669875

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2008-05-159624

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36969778&oldid=1664998073"